DIMERIX INVESTOR CALL & PRESENTATION
Dimerix
Immediate Release
DIMERIX INVESTOR CALL & PRESENTATION
MELBOURNE, Australia, 1 March 2022: Dimerix Limited (ASX: DXB), a clinical-stage
biopharmaceutical company invites shareholders to attend its investor webinar held today at
11am (AEDT) 1 March 2022.
The webinar will cover Dimerix' activities, including the announcement regarding the changes to
the REMAP-CAP COVID-19 study.
Interested parties can register for the webinar using this link:
https://zoom.us/webinar/register/WN_q1mnHbYTStClbQ_ClejUwg
An investor presentation is attached to this announcement. Participants may submit questions
during registration or during the session.
For further information, please visit our website at www.dimerix.com or contact:
Dr Nina Webster
Dimerix Limited
Chief Executive Officer & Managing Director
Tel: +61 1300 813 321
E: [email protected]
Follow us on LinkedIn and Twitter
Rudi Michelson
Monsoon Communications
Tel: +61 3 9620 3333
Mob: +61 (0)411 402 737
E: [email protected]
Authorised for lodgement by the Board of the Company
-END-
About Dimerix
Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with
unmet medical needs for global markets. Dimerix is currently developing its proprietary product DMX-200, for Focal
Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and Diabetic Kidney
Disease, and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). DMX-200 and DMX-700
were both identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT),
which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions
to rapidly screen and identify new drug opportunities. Receptor-HIT is licensed non-exclusively to Excellerate
Bioscience, a UK-based pharmacological assay service provider with a worldwide reputation for excellence in the field
of molecular and cellular pharmacology.
About DMX-200
DMX-200 is the adjunct therapy of a chemokine receptor (CCR2) antagonist administered to patients already
receiving an angiotensin II type I receptor (AT1R) blocker - the standard of care treatment for hypertension and kidney
disease¹. DMX-200 is protected by granted patents in various territories until 2032, with additional applications
submitted that may extend the protection to 2042 if granted.
DMX-200 has demonstrated encouraging data that could provide meaningful clinical outcomes for patients with
kidney disease across 4 clinical studies to date¹. DMX-200 is also under investigation as a potential treatment for
patients with COVID-19 in two separate studies: REMAP-CAP and CLARITY 2.0.
References
1 ASX releases: 12Jul17, 180ct17, 27Mar18, 29Jul20, 14Sep20, 27Oct20, 28Jan21, 24Mar21, 03Jun21, 07Jun21, 19Jul21
Dimerix is a biopharmaceutical
company developing innovative new
therapies in areas with unmet
medical needs.
Dimerix HQ
425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. [email protected]View entire presentation